The Trump administration’s 2025 drug policy agenda omits cannabis rescheduling, despite earlier signals of support, instead prioritizing fentanyl, border security, and addiction treatment. This omission, coupled with a stalled DEA rescheduling process, has added to industry uncertainty and is frustrating reform advocates, especially as federal restrictions on interstate trade are blamed for fueling the illicit market. Separately, the DOJ’s decision to stop defending DEA legal protections may accelerate cannabis research, and bipartisan voices, including Sen. Fetterman and GOP Sen. Yaw, are pushing for federal legalization.
Please see full publication below for more information.
